Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma |
Pujani, Mukta
(ESIC Medical College)
Makker, Isha (Hamdard Institute of Medical Sciences and Research) Makker, Annu (King George's Medical University) Goel, Madhu Mati (King George's Medical University) Jetley, Sujata (Hamdard Institute of Medical Sciences and Research) |
1 | Goldin RD, Roa JC (2009). Gallbladder cancer: a morphological and molecular update. Histopathol, 55, 218-29. DOI |
2 | Grau LAH, Badia JM, Salvador CA, et al (2004). Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen as prognostic markers. HPB (Oxford), 6, 174-80. DOI |
3 | Harder J, Waiz O, Otto F (2009). EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol, 15, 4511-7. DOI |
4 | Hui AM, Shi YZ, Li X, et al (2002). Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett, 176, 191-8. DOI |
5 | Hundal R, Shaffer EA (2014). Gallbladder Cancer: epidemiology and outcome. Clin Epidemiol, 6, 99-109. |
6 | Javle M, Churi C, Kang HSC, et al (2015). HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol, 8, 58. DOI |
7 | Kai K, Masuda M, Ide T, et al (2013). Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor. Mol Clin Oncol, 1, 633-8. DOI |
8 | Kapoor VK, McMichael AJ (2003). Gallbladder cancer: an ‘Indian’ disease. Natl Med J India, 16, 209-13. |
9 | Kawamoto T, Krishnamurthy S, Tarco E, et al (2007). HER receptor family: novel candidate for targeted therapy for gall bladder and extrahepatic bile duct cancer. Gastrointest Cancer Res, 1, 221-7. |
10 | Kim YW, Huh SH, Park YK (2001). Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep, 8, 1127-32. |
11 | Kumari N, Kapoor VK, Krishnani N, et al (2012). Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol, 55, 75-9. DOI |
12 | Matsuyama S, Kitajima Y, Sumi K, et al (2004). Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. Oncol Rep, 11, 815-9. |
13 | Mitri Z, Constantine T, O'Regan (2012). The HER2 receptor in breast cancer: pathophysiology: clinical use, and new advances in therapy. Chemother Res Pract, 2012, 743193. |
14 | Nakazawa K, Dobashi Y, Suzuki S, et al (2005). Amplification and overexpression of C-erbB2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol, 206, 356-65. DOI |
15 | Puhalla H, Wrba F, Kandioler D (2007). Expression of p21(Waf1/ Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res, 27, 1679-84. |
16 | Rakic M, Patrlj L, Kopljar M, et al (2014). Gallbladder cancer. Hepatobiliary Surg Nutr, 3, 221-6. |
17 | Roa EI, Elorza DX, Lantadilla HS, et al (2009). Immunohistochemical expression of Ki67 as a marker of proliferation in gallbladder mucosa samples with or without cancer. Rev Med Chil, 137, 881-7. |
18 | Roa I, de Toro G, Schalper K, et al (2014). Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointestinal Cancer Res, 7, 42-8. |
19 | Shrestha ML, Miyake H, Kikutsuji T, et al (1998). Prognostic significance of Ki67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J med Invest, 45, 95-102. |
20 | Artico M, Bronzetti E, Alicino V, et al (2010). Human gallbladder carcinoma: Role of neutrophins, MIB-1, CD34 and CA15-3. Eur J Histo, 54, 10. DOI |
21 | Dhir V, Mohandas KM (1999). Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol, 18, 24-8. |
22 | Toledo C, Matus CE, Barraza X, et al (2012). Expression of HER2 and bradykinin B1 receptors in precursor lesions of gallbladder carcinoma. World J Gastroenterol, 18, 1208-15. DOI |
23 | Barreto SG, Dutt A, Chaudhary A (2014). A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol, 25, 1086-97. DOI |
24 | Bizama C, Garcia P, Espinoza JA, et al (2015). Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev, 41, 222-34. DOI |
25 | Chaube A, Tewari M, Garbyal RS, et al (2006). Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients. BMC Cancer, 6, 126. DOI |
26 | Chua TC, Merrett ND (2012). Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer, 130, 2845-56. DOI |
27 | Ghosh Y, Thakurdas B (2015). Carcinoma gallbladder: A review of literature. Int J Scien Study, 2, 98-103. |
28 | Doval DC, Azam S, Sinha R, et al (2014). Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma. J Carcinog, 13, 10. DOI |